Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M24-147: Livmoniplimab + budigalimab vs TKI in previously treated hepatocellular carcinoma
jRCT2031230144Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised trial of livmoniplimab and budigalimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Best Overall Response (BOR) per Investigator. Started Jul 2023; status: active, not recruiting.
02
Drugs
livmoniplimabbudigalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031230144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230144.